Merck to Unveil Latest Findings at 2024 ASCO Annual Meeting Showcasing Progress in Innovative Oncology Treatments Across Extensive Portfolio and Varied Pipeline
NextEdge Admin
17 May 2024
4 min 3 sec
0
Merck, also known as MSD outside the United States and Canada, is set to unveil a wealth of data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, spanning various oncology medicines and pipeline candidates targeting over 25 types of cancer. These presentations highlight Merck’s ongoing commitment to advancing cancer research across a diverse range of therapies.
Dr. Marjorie Green, Merck’s senior vice president and head of oncology at global clinical development, emphasized the significance of the breadth of data being presented, reflecting the company’s dedication to driving innovations in oncology. As the meeting coincides with nearly a decade since the initial approval of KEYTRUDA in the U.S., Dr. Green acknowledged the transformative impact this period has had on the oncology treatment landscape, attributing it to the collaborative efforts of patients, researchers, and physicians worldwide.
Among the notable presentations are updates on KEYTRUDA, Merck’s flagship oncology therapy, including long-term follow-up data in advanced gastrointestinal cancers and melanoma, as well as quality of life and patient-reported outcomes data in metastatic bladder and non-small cell lung cancer settings.
Highlighted data for KEYTRUDA includes:
– Three-year follow-up data from the KEYNOTE-966 study in advanced biliary tract cancer.
– Longer-term follow-up results from the KEYNOTE-859 study in advanced gastric or gastroesophageal junction cancer.
– Patient-reported outcomes from the KEYNOTE-A39/EV-302 trial in previously untreated locally advanced or metastatic urothelial cancer.
– Health-related quality of life data from the KEYNOTE-671 study in resectable stage II, IIIA or IIIB non-small cell lung cancer.
– Updated efficacy and safety data from the KEYNOTE-224 study in advanced hepatocellular carcinoma.
– Long-term data from the KEYNOTE-629 study in recurrent/metastatic or locally advanced cutaneous squamous cell carcinoma.
In addition to KEYTRUDA updates, Merck will present data on several investigational candidates, including mRNA-4157, vibostolimab/pembrolizumab, sacituzumab tirumotecan, and patritumab deruxtecan, with a focus on combination therapies involving KEYTRUDA.
Key pipeline data to be presented includes:
– Three-year follow-up data from the KEYNOTE-942/mRNA-4157-P201 trial in combination with KEYTRUDA for resected high-risk melanoma.
– Phase 3 study results evaluating sacituzumab tirumotecan in China for previously treated locally recurrent or metastatic TNBC.
– Phase 2 study data from China evaluating sacituzumab tirumotecan in combination with KL-A167 as first-line treatment for advanced NSCLC.
– Cohort B1 data from the KeyVibe-005 study evaluating vibostolimab/pembrolizumab in previously treated advanced mismatch repair-deficient endometrial cancer.
These presentations underscore Merck’s commitment to advancing cancer care through innovative therapies and collaborative research efforts.
